THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIES OR MAY QUALIFY AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (EUWA).
GlaxoSmithKline Capital plc announces the repurchase and cancellation of certain outstanding GBP Notes
13 February 2023
GlaxoSmithKline Capital plc (the Company) announces today that it has purchased and cancelled the following GBP Notes issued under the Group's Euro Medium Term Note Programme:
|
Description of the Notes |
ISIN / Common Code |
Nominal amount of GBP Notes purchased and cancelled |
Aggregate Nominal Amount Outstanding after such purchase and cancellations |
|
5.250 per cent. Notes due 19 December 2033 |
XS0140516864/ 014051686 |
£75,783,000 |
£574,166,000 |
|
6.375 per cent. Notes due 9 March 2039 |
XS0350820931/ 035082093 |
£68,700,000 |
£631,300,000 |
The Company
GlaxoSmithKline Capital plc
980 Great West Road
Brentford
Middlesex TW8 9GS
United Kingdom
Email: company.secretary@gsk.com
This announcement contains information that qualifies or may qualify as inside information. The person responsible for arranging the release of this announcement on behalf of GlaxoSmithKline Capital plc is Victoria Whyte, Company Secretary.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
